Medication info

Nexfarm Ibandronate Injection (Ibandronic Acid Sodium Hydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Nexfarm Korea Co., Ltd.
Appearance
A colorless, transparent solution in a colorless, transparent glass pre-filled syringe with a single-use injection needle attached.
Packaging
3ml/pre-filled syringe X 1
Approval status
Active

MFDS item code 201701085 · Notified 2017.02.28 · Insurance code 649103381,662505191

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15-30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment: No dose adjustment is necessary. No dose adjustment is necessary in patients with mild or moderate renal impairment with a serum creatinine of 200µmol/L(2.3mg/dL) or less or a creatinine clearance of 30ml/min or greater. Because clinical experience is insufficient in patients with a serum creatinine greater than 200µmol/L(2.3mg/dL) or a creatinine clearance below 30ml/min, use of this medicine is not recommended. Older adults: No dose adjustment is necessary.
Child administration
Children 18 years of age or younger: Efficacy and safety have not been studied.

Ingredients

Manufacturer
Nexfarm Korea Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used for the treatment of osteoporosis in postmenopausal women. It helps to increase bone density, strengthen bones, and reduce the risk of fractures.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15-30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment: No dose adjustment is necessary. No dose adjustment is necessary in patients with mild or moderate renal impairment with a serum creatinine of 200µmol/L(2.3mg/dL) or less or a creatinine clearance of 30ml/min or greater. Because clinical experience is insufficient in patients with a serum creatinine greater than 200µmol/L(2.3mg/dL) or a creatinine clearance below 30ml/min, use of this medicine is not recommended. Older adults: No dose adjustment is necessary.

Child administration

Children 18 years of age or younger: Efficacy and safety have not been studied.

Precautions

This medication must be administered intravenously, and caution should be exercised as tissue damage may occur if administered intra-arterially or around the vein. It should not be used in patients with known hypersensitivity to this drug or its components, or in patients with untreated hypocalcemia. Gastric-related symptoms such as gastritis, diarrhea, abdominal pain, indigestion, nausea, and constipation may occur while taking this medication, as well as musculoskeletal pain such as myalgia and arthralgia. Some patients may experience influenza-like symptoms, fatigue, headache, and rash, typically of mild to moderate severity, and recovery occurs without discontinuation of treatment. Adequate intake of calcium and vitamin D is important while using this drug, and supplements should be taken if there is a deficiency. Serious side effects such as osteonecrosis of the jaw have been reported, especially in cancer patients or those taking certain medications; a thorough examination of oral health before dental treatment is recommended, and excessive dental procedures should be avoided during treatment. Additionally, very rarely, serious adverse reactions such as osteonecrosis of the outer ear, severe allergic reactions, skin reactions, and atypical fractures may occur; report any unusual symptoms to healthcare providers immediately. This drug is not metabolized by the liver and is primarily excreted through the kidneys, so patients with impaired kidney function should undergo regular examinations, and monitoring of kidney and liver function should be increased in cases of overdose. Safety during pregnancy or lactation has not been established, so its use is not recommended. This drug should not be mixed with other calcium-containing solutions and used syringes and needles should not be reused but safely discarded. Lastly, the effects on driving or operating machinery are unknown, so caution is advised.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reactions, thrombophlebitis, hypersensitivity reactions, angioedema, facial swelling/edema, hives, osteonecrosis of the jaw and external ear, uveitis, episcleritis, scleritis, anaphylactic reactions/shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral shaft and intertrochanteric fractures, atypical fractures of the iliac bone, dizziness, optic atrophy, lower motor neuron lesions, tremor, unspecified gastrointestinal disorders, benign gastrointestinal tumors, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin exfoliation, sensory impairment, acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air or moisture, ideally at room temperature between 1 and 30 degrees Celsius. Proper storage helps to maintain the effectiveness and safety of the drug.

Appearance and packaging

Appearance

A colorless, transparent solution in a colorless, transparent glass pre-filled syringe with a single-use injection needle attached.

Package unit

3ml/pre-filled syringe X 1

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.